Earnings ·
OPKO reports Q3 loss of $0.05 per share and agrees to sell BioReference for up to $872M
OPKOpko Health, Inc.
OPKO Health reported a net loss from continuing operations of $35.5 million, or $0.05 per share, for the third quarter ended September 30, 2026, compared to a $33.0 million loss in the prior-year period. Revenue increased 16% to $65.4 million, driven by higher royalty revenue from Eli Lilly and growth in international operations. The company also announced an agreement with Labcorp to sell substantially all remaining BioReference diagnostic operations for $722 million in cash at closing, plus up to $150 million in additional consideration based on future sales of the 4Kscore test. Additionally, OPKO expanded its strategic relationship with HealthCare Royalty through a $125 million financing secured by royalty payments from its license agreement with Eli Lilly related to mazdutide. The multinational biopharmaceutical company develops and delivers therapeutics for serious diseases across global markets.